DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients

Information source: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Obstructive Pulmonary Disease

Intervention: Salbutamol + Tiotropium (Drug); Placebo + Tiotropium (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi

Summary

The aim of this study is to assess the effects on respiratory mechanics of one "classical" short-term bronchodilator (i. e., salbutamol) versus placebo, and to verify the hypothesis that the addition of another bronchodilator (i. e., anticholinergic) may induce a further improvement on the work of breathing of stable COPD patients.

Clinical Details

Official title: Effect of Bronchodilators on Respiratory Mechanics in COPD Patients With Poor Reversibility

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Recordings of respiratory mechanics

Secondary outcome: Dyspnea score

Detailed description: Studies with long-acting b2-agonists in COPD patients who poorly respond to routine airways obstruction reversibility tests with forced expiratory manoeuvres, such as forced expiratory volume in one second (FEV1), are scarce. Such studies, however, seem to show favourable effects on clinical parameters. This may explain the subjective improvements and changes in quality of life with long-acting b2-agonists in patients with COPD. The lack of effect on forced expiration tests may be due to early airway collapse and subsequent airflow decline causing underestimation of the existing bronchodilatory effects located more peripherally in the respiratory tract, where the major site of resistance is located in obstructive lung disease. We therefore design a study aimed to assess the short term effects of one short-acting beta2-agonist vs placebo, and the effects of an additional and sequential administration of a different bronchodilator, like tiotropium bromide (anticholinergic agent) on the work of breathing, and its components (i. e., lung resistances and compliance) of COPD patients with poor reversibility assessed using the classical Pulmonary Function Tests.

Eligibility

Minimum age: 20 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- COPD patient with a Tiffenau ratio <55% and >25% predicted

- Poor reversibility to an acute bronchodilator test (i. e. FEV1 changes<10% from

baseline) Exclusion Criteria:

- Lack of informed consent

- Cancer

- Concomitant lung and airways diseases

Locations and Contacts

Respiratory Unit Fondazione S.Maugeri, Pavia, PV 27100, Italy
Additional Information

Starting date: September 2008
Last updated: July 16, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017